What is PN-477?
PN-477 is a next-generation peptide being developed by Protagonist Therapeutics as a GLP-1 / GIP / GCGR triple agonist. It targets the same receptors influenced by popular drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) — but aims to go even further by adding glucagon activity to increase fat oxidation and energy expenditure.
Still in preclinical development, PN-477 is being tested as a treatment for:
- Obesity (BMI >30)
- Type 2 Diabetes
- Insulin resistance and metabolic syndrome
- NAFLD and NASH (liver fat conditions)
Why is PN-477 Different?
Unlike single or dual agonists, PN-477 mimics three hormone pathways at once:
- GLP-1: Suppresses appetite, improves insulin secretion
- GIP: Enhances insulin response, protects beta cells
- GCGR (glucagon): Boosts fat burning and thermogenesis
This triple action could result in greater weight loss, better glycemic control, and body recomposition versus current options.
Benefits Being Studied:
- Up to 30% weight loss in animal trials
- Significant HbA1c reduction
- Fat loss without muscle loss
- Improved insulin sensitivity
Explore the PN-477 Knowledge Base:
Frequently Asked Questions (FAQ)
When will PN-477 be available?
Clinical trials are expected to begin in 2026, with commercial availability likely no earlier than 2029 depending on FDA approval.
Is PN-477 stronger than semaglutide?
Early research in animals suggests greater fat loss and better insulin sensitivity — but human results are still needed to confirm.
Can I buy PN-477 online?
No. PN-477 is not yet approved or for sale anywhere. Be cautious of scammers.
For more answers, see our full blog posts or ask in our Discord community.